AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04222764 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Real-time three-dimensional echocardiography
Description: The initial hemodynamic assessment and monitoring using echocardiography will be performed within 12h following ICU admission. TTE will be performed systematically as first-line examination and TEE will be performed only on ventilated and sedated patients for whom additional information is required for their management, according to the standards of care of the participating centers. In that case, TEE will be performed immediately after TTE.~3D echocardiographic measurements will be performed after the examination by two independent intensivists expert in critical care echocardiography who will be blinded from the usual parameters of RV systolic functions; these parameters will be measured during the examination to guide the management of patients, according to the standard of care of the participating centers.
Study NCT04725877 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VIR-1111
Description: VIR-1111 is administered as a 1 mL subcutaneous injection in the deltoid area of the upper arm on Day 1 and Day 57.
Study NCT04725877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo (Tris NaCl Sucrose formulation buffer) given by subcutaneous injection.
Study NCT02227979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Purple Cry Intervention
Description: This intervention consists of an 11-page booklet and 12-minute DVD produced by the National Center on Shaken Infant Syndrome.
Study NCT02227979 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: This intervention consist of 1 brochure and a DVD on infant safety excerpted from the Safe Start video on infant safety.
Study NCT00979550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: commercially available topical antiviral drug
Study NCT00979550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: non-medicated petroleum cream
Description: Over the counter topical cream used to aid the healing process in skin lesions
Study NCT03304197 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hypotonic
Description: N/A: see arm description
Study NCT03304197 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isotonic
Description: N/A: see arm description
Study NCT03304197 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: N/A: see arm description
Study NCT03304197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dehydrated
Description: N/A: see arm description
Study NCT04110704 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of transvaginal cerclage
Description: Transvaginal cerclage is inserted in women with a high risk of preterm birth. However it is unknown whether this alongside cervical length monitoring improves the incidence of preterm birth. The cerclage is inserted under regional analgesia.
Study NCT03011996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 50mg
Description: Cohort 2: bid for 7 days
Study NCT03011996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMX 1g
Description: Cohort 1: bid for 5 days Cohort 2: bid for 7 days
Study NCT03011996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMX 1g
Description: Cohort 1: bid for 5 days Cohort 2: bid for 7 days
Study NCT03011996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole 40mg
Description: Cohort 2: bid for 7 days
Study NCT01208272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Study NCT01208272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Therapy (IPT)
Study NCT02414282 — intervention group
Intervention type: DRUG
Intervention: F 18 T807
Description: Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
Study NCT01271647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yin and Yang tonic granules
Description: Yin and Yang tonic granules,18g per time,two times per day,six months
Study NCT01271647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: granules,18g per time,two times per day,six months
Study NCT02772666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: O-Glass
Description: The new diagnostic device to distinguish relative afferent pupillary defect(RAPD).
Study NCT02772666 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Swinging Flashlight Test
Description: The swinging-flashlight test is used to help a practitioner identify a relative afferent pupillary defect.For an adequate test, vision must not be entirely lost. In dim room light, the examiner notes the size of the pupils. The patient is asked to gaze into the distance, and the examiner swings the beam of a penlight back and forth from one pupil to the other, and observes the size of pupils and reaction in the eye that is lit.
Study NCT03544853 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prosthetic socket for transtibial amputee
Description: To wear a prosthetic socket for evaluation of comfort and biomechanical metrics such as skin loading conditions.
Study NCT03753698 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eCoin
Description: Implantation of device electrodes subcutaneous in lower tibia area;~Stimulation of posterior tibial nerves:~Regimen 1 (months 0-3): Six stimulation treatments per week, one stimulation per day, for duration of 30 minutes each Regimen 2 (months 3-6): Three stimulation treatments per week, one stimulation per day, for duration of 30 minutes each. Stimulation is activated by the patient.
Study NCT02117453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 20 mg/day
Study NCT02117453 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03339245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose Solution (75 Grams)
Description: Fructose given in divided doses at breakfast and dinner.
Study NCT03339245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose Solution (75 grams)
Description: Glucose given in divided doses at breakfast and dinner.
Study NCT01342341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parafon Forte
Description: Drug: Parafon Forte administered at study visit~Other: Placebo administered at study visit
Study NCT01342341 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Parafon Forte
Description: Drug: Parafon Forte administered at study visit~Other: Placebo administered at study visit
Study NCT02880410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroBlate System
Description: Laser Interstitial Thermal Therapy
Study NCT02880410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation therapy and temozolomide
Description: Radiation therapy and temozolomide
Study NCT00727311 — intervention group
Intervention type: BIOLOGICAL
Intervention: PegIntron (peginterferon alfa-2b; SCH 54031) injector
Description: PegIntron administered at a dose 1.5 μg/kg/week, according to the Summary of Product Characteristics (SPC) and approved European labeling
Study NCT00727311 — intervention group
Intervention type: DRUG
Intervention: Rebetol (ribavirin; SCH 18908)
Description: Rebetol administered at a dose of 800-1200 mg/day (on a weight-basis) according to the SPC and approved European labeling
Study NCT02952534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib will be administered daily
Study NCT04196491 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bb2121
Description: CAR-T Cell Therapy
Study NCT01046864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: IV solution, IV bolus over 2-4 minutes, 400 mg/m², Every 14 days, Until disease progression/toxicity
Study NCT04196491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting Chemotherapy
Study NCT04196491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting Chemotherapy
Study NCT04196491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Maintenance Therapy
Study NCT01684787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a + ribavirin in normal ALT
Description: peginterferon alfa-2a 180 mcg/weekly ribavirin 1000-1200 mg/daily
Study NCT01684787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a + ribavirin in elevated ALT
Description: peginterferon alfa-2a 180 mcg/weekly ribavirin 1000-1200 mg/daily
Study NCT00962377 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endomyocardial biopsy
Description: Right ventricular endomyocardial biopsy in monitoring of asymptomatic heart transplant patients for acute cellular rejection
Study NCT00962377 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: AlloMap Molecular Testing
Description: Gene expression profiling in the monitoring of asymptomatic heart transplant patients for acute cellular rejection.
Study NCT03995862 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: A questionnaire should be completed by the patient the day of inclusion. Health data will be collected in patients medical file from inclusion to the date of the end of study (i.e. no follow-up for the last patient included and a maximum of three years of follow-up for the first patient included).
Study NCT03341325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: animal-assisted activity
Description: a live animal (small dog and/or rabbit)
Study NCT03341325 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control activity
Description: a stuffed toy animal
Study NCT04075877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOCUS
Description: See prior section.
Study NCT02780908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graded exercise testing
Description: All graded exercise tests will be performed on electromagnetically controlled cycle-ergometer Ergo Bike Premium. The testing protocol will commence with a 10-min resting period, to obtain the resting cardio-respiratory values, followed by a 5-min warm up at a work rate of 60 W. Thereafter the workload will increase every fourth minute by 40 W. The participants will be required to maintain a cadence of 60·min-1 throughout the whole test. The test is terminated when the participant is unable to maintain the assigned cadence.
Study NCT02780908 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Graded exercise testing
Description: All graded exercise tests will be performed on electromagnetically controlled cycle-ergometer Ergo Bike Premium. The testing protocol will commence with a 10-min resting period, to obtain the resting cardio-respiratory values, followed by a 5-min warm up at a work rate of 60 W. Thereafter the workload will increase every fourth minute by 40 W. The participants will be required to maintain a cadence of 60·min-1 throughout the whole test. The test is terminated when the participant is unable to maintain the assigned cadence.
Study NCT02780908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resting testing
Description: The resting test will be performed in supine position with participants breathing normoxic air (FiO2=0.21) for 30 min and hypoxic gas for the subsequent 30-min (FiO2=0.120). During the whole protocol duration the respiration, local blood flow, ECG and EEG will be measured non-invasively.
Study NCT02780908 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resting testing
Description: The resting test will be performed in supine position with participants breathing normoxic air (FiO2=0.21) for 30 min and hypoxic gas for the subsequent 30-min (FiO2=0.120). During the whole protocol duration the respiration, local blood flow, ECG and EEG will be measured non-invasively.
Study NCT03730129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hizentra
Description: Subjects will receive Hizentra 0.4 mg/kg qweekly subcutaneously for 6 months (24 weeks)
Study NCT00658255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol
Study NCT00658255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: formoterol
Study NCT03053687 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation standardized formula
Description: Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
Study NCT03053687 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Low caloric formula (Powder added to water) without added vitamins and mineral
Study NCT01395459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IVR only
Description: As noted, patients in this arm receive consistent, but spaced out calls generated by an interactive voice response system reminding them of breast, cervical and colon cancer screenings needed, as applicable.
Study NCT01395459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IVR+PCC
Description: Interactive voice response calls followed up by prevention care coordinator calls for those who do not respond to IVR
Study NCT00106210 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early intervention blending several tx approaches, w/ focus
Description: Early intervention blending several different treatment approaches, with a focus on certain skills
Study NCT00106210 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early intervention blending several treatment approaches
Description: Early intervention blending several different treatment approaches
Study NCT02321202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acid-Based Parenteral Nutrition
Description: Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 fatty acid \[FA\] mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively.
Study NCT02321202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Structolipid
Description: Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 FA mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively.
Study NCT02295943 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Positioning measuring device
Description: Vitrectomy, intraocular gas fill. The supine time during the first postoperative day is measured
Study NCT02999802 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Progressive resistance exercise training
Study NCT02169362 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autologous Platelet Rich Plasma (PRP) Gel (Magellan® Bio-Bandage™)
Description: Application of up to 18 mL of autologous PRP gel (Magellan® Bio-Bandage™) to the surface of an acute deep partial thickness burn wound no greater than 72 cm squared within 72 hours of the initial injury. Intervention is in addition to standard of care treatment. The PRP Bio-Bandage™ is prepared using the Magellan® System and is FDA cleared via BK030040 and BK040068.
Study NCT02169362 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Autologous Platelet Rich Plasma (PRP) Gel (Magellan® Bio-Bandage™)
Description: Application of up to 18 mL of autologous PRP gel (Magellan® Bio-Bandage™) to the surface of an acute deep partial thickness burn wound no greater than 72 cm squared within 72 hours of the initial injury. Intervention is in addition to standard of care treatment. The PRP Bio-Bandage™ is prepared using the Magellan® System and is FDA cleared via BK030040 and BK040068.
Study NCT02823990 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG4010
Description: Given SC
Study NCT02823990 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03134105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monthly Feedback on activity and patient-reported angina
Description: Providers will receive monthly updates on step count and patient reported angina for each of their patients, with data derived from a wearable fitness tracker and every other week emailed surveys
Study NCT03134105 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: End-of-Study Feedback
Description: Providers will receive an end-of-study update on step count and patient reported angina for each of their patients, with data derived from a wearable fitness tracker and every other week emailed surveys
Study NCT04165031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3499446
Description: Administered orally
Study NCT04165031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study NCT04165031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered IV
Study NCT04165031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Administered orally
Study NCT04165031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Administered IV
Study NCT03293160 — intervention group
Intervention type: OTHER
Intervention: Care management services
Description: Patients who receive care management services will interact with a care manager who will take an inventory of the patient's needs (including social determinants of health such as housing) and provide guidance about available social supports and clinical resources.
Study NCT00039390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally (PO)
Study NCT00039390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given PO
Study NCT00039390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00039390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01695031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored asthma management program
Description: web-based, computer-tailored asthma management intervention delivered every week for 4 weeks
Study NCT01695031 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Generic web-based education
Description: Generic, web-based asthma education
Study NCT01132443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin 1%-Benzoyl Peroxide (BPO) 3% Gel,
Description: Apply topically once daily
Study NCT01132443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin 1%-Benzoyl Peroxide (BPO) 3% Gel,
Description: Apply topically once daily
Study NCT00130260 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Staph aureus types 5 and 8 conjugate vaccine
Description: each IM dose contains 200 mc total conjugate
Study NCT00130260 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo to match StaphVAX
Study NCT01133795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine plus Albumin
Description: MIdodrine 10mg tid for 12 weeks. Albumin 40g every 14 days for 12 weeks
Study NCT00921687 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education only
Description: The education will consist of a lecture and distribution of a CKD reference card.
Study NCT00921687 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention
Description: Providers in the intervention group will receive a lecture on CKD, a CKD reference card, academic detailing (residents only), and access to the CKD registry.
Study NCT03787459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbidol
Description: Oseltamivir plus Arbidol will be administrated from Days 1-7.
Study NCT03787459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Oseltamivir plus placebos will be administrated from Days 1-7.
Study NCT02270541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: In-ambulance telemedicine
Study NCT02767284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UCST-V1
Description: A previously developed device, Uppsala Contrast Sensitivity Tester - UCST-V1, that quickly measures the human CSF in one stimulus.
Study NCT02767284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UCST-V2
Description: A refined version of the UCST-V1 that randomizes frequency order.
Study NCT02767284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UCST-V3
Description: A version that utilises eye-tracking technology to make the measurements more accurate.